Buyout firm Clayton, Dubilier & Rice agreed to acquire UDG Healthcare for £2.61 billion (US$3.7 billion) in cash, the latest in a flurry of pharmaceutical deals amid the pandemic.
UDG investors will receive 1,023 pence a share, about 22% more than the closing price on May 11, the Dublin-based company said in a statement Wednesday, May 12. The shares briefly jumped above the offer price, and traded at 1,022 pence by 9:27 a.m. in London.
The pace of health-care acquisitions has accelerated during the pandemic, and UDG, which provides a range of services to pharmaceutical customers in about 25 countries, stated it’s supporting clients in bringing COVID treatments and vaccines to market. The company reported adjusted operating profit growth of 11% in the fiscal first half.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Government Launches New Agency to Fast-Track Tech Regulation
Oct 8, 2024 by
CPI
McDonald’s Sues Beef Giants, Accusing Them of Price-Fixing Conspiracy
Oct 8, 2024 by
CPI
Federal Judge Orders Google to Open Android App Store Amid Antitrust Pressure
Oct 7, 2024 by
CPI
Federal Judge Greenlights FTC’s Antitrust Lawsuit Against Amazon, Tosses Some State Claims
Oct 7, 2024 by
CPI
Supreme Court Rejects Uber and Lyft’s Appeal in California Gig Worker Suits
Oct 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh